Scutelnic, AdrianAdrianScutelnicKrzywicka, KatarzynaKatarzynaKrzywickaMbroh, JoshuaJoshuaMbrohvan de Munckhof, AnitaAnitavan de MunckhofSánchez van Kammen, MayteMayteSánchez van KammenAguiar de Sousa, DianaDianaAguiar de SousaLindgren, ErikErikLindgrenJood, KatarinaKatarinaJoodGünther, AlbrechtAlbrechtGüntherHiltunen, SiniSiniHiltunenPutaala, JukkaJukkaPutaalaTiede, AndreasAndreasTiedeMaier, FrankFrankMaierKern, RolfRolfKernBartsch, ThorstenThorstenBartschAlthaus, KatharinaKatharinaAlthausCiccone, AlfonsoAlfonsoCicconeWiedmann, MarkusMarkusWiedmannSkjelland, MonaMonaSkjellandMedina, AntonioAntonioMedinaCuadrado-Godia, ElisaElisaCuadrado-GodiaCox, ThomasThomasCoxAujayeb, AvinashAvinashAujayebRaposo, NicolasNicolasRaposoGarambois, KatiaKatiaGaramboisPayen, Jean-FrancoisJean-FrancoisPayenVuillier, FabriceFabriceVuillierFranchineau, GuillaumeGuillaumeFranchineauTimsit, SergeSergeTimsitBougon, DavidDavidBougonDubois, Marie-CécileMarie-CécileDuboisTawa, AudreyAudreyTawaTracol, ClementClementTracolDe Maistre, EmmanuelEmmanuelDe MaistreBonneville, FabriceFabriceBonnevilleVayne, CarolineCarolineVayneMengel, AnneroseAnneroseMengelMichalski, DominikDominikMichalskiPelz, JohannJohannPelzWittstock, MatthiasMatthiasWittstockBode, FelixFelixBodeZimmermann, JulianJulianZimmermannSchouten, JudithJudithSchoutenButure, AlinaAlinaButureMurphy, SeanSeanMurphyPalma, VincenzoVincenzoPalmaNegro, AlbertoAlbertoNegroGutschalk, AlexanderAlexanderGutschalkNagel, SimonSimonNagelSchoenenberger, SilviaSilviaSchoenenbergerFrisullo, GiovanniGiovanniFrisulloZanferrari, CarlaCarlaZanferrariGrillo, FrancescoFrancescoGrilloGiammello, FabrizioFabrizioGiammelloMartin, Mar MorinMar MorinMartinCervera, AlvaroAlvaroCerveraBurrow, JimJimBurrowGarcia Esperon, CarlosCarlosGarcia EsperonChew, Beng Lim AlvinBeng Lim AlvinChewKleinig, Timothy JTimothy JKleinigSoriano, CristinaCristinaSorianoZimatore, Domenico SDomenico SZimatorePetruzzellis, MarcoMarcoPetruzzellisElkady, AhmedAhmedElkadyMiranda, Miguel SMiguel SMirandaFernandes, JoãoJoãoFernandesHellström Vogel, ÅslögÅslögHellström VogelJohansson, EliasEliasJohanssonPhilip, Anemon PuthuppallilAnemon PuthuppallilPhilipCoutts, Shelagh BShelagh BCouttsBal, SimerpreetSimerpreetBalBuck, BrianBrianBuckLegault, CatherineCatherineLegaultBlacquiere, DylanDylanBlacquiereKatzberg, Hans DHans DKatzbergField, Thalia SThalia SFieldDizonno, VanessaVanessaDizonnoGattringer, ThomasThomasGattringerJacobi, ChristianChristianJacobiDevroye, AnnemieAnnemieDevroyeLemmens, RobinRobinLemmensKristoffersen, Espen SaxhaugEspen SaxhaugKristoffersenBandettini di Poggio, MonicaMonicaBandettini di PoggioGhiasian, MasoudMasoudGhiasianKarapanayiotides, TheodorosTheodorosKarapanayiotidesChatterton, SophieSophieChattertonWronski, MiriamMiriamWronskiNg, KarlKarlNgKahnis, RobertRobertKahnisGeeraerts, ThomasThomasGeeraertsReiner, PeggyPeggyReinerCordonnier, CharlotteCharlotteCordonnierMiddeldorp, SaskiaSaskiaMiddeldorpLevi, MarcelMarcelLevivan Gorp, Eric C MEric C Mvan Gorpvan de Beek, DiederikDiederikvan de BeekBrodard, JustineJustineBrodardKremer Hovinga Strebel, Johanna AnnaJohanna AnnaKremer Hovinga Strebel0000-0002-1300-7135Kruip, Marieke J H AMarieke J H AKruipTatlisumak, TurgutTurgutTatlisumakFerro, José MJosé MFerroCoutinho, Jonathan MJonathan MCoutinhoArnold, MarcelMarcelArnoldPoli, SvenSvenPoliHeldner, Mirjam RachelMirjam RachelHeldner0000-0002-3594-21592024-10-112024-10-112022-10https://boris-portal.unibe.ch/handle/20.500.12422/85562OBJECTIVE Cerebral venous thrombosis caused by vaccine-induced immune thrombotic thrombocytopenia (VITT-CVT) is a rare adverse effect of adenovirus-based SARS-CoV-2 vaccines. In March 2021, after autoimmune pathogenesis of VITT was discovered, treatment recommendations were developed. These comprised immunomodulation, non-heparin anticoagulants, and avoidance of platelet transfusion. The aim of this study was to evaluate adherence to these recommendations and its association with mortality. METHODS We used data from an international prospective registry of patients with CVT after adenovirus-based SARS-CoV-2 vaccination. We analyzed possible, probable or definite VITT-CVT cases included until 18 January 2022. Immunomodulation entailed administration of intravenous immunoglobulins and/or plasmapheresis. RESULTS 99 VITT-CVT patients from 71 hospitals in 17 countries were analyzed. Five of 38 (13%), 11/24 (46%), and 28/37 (76%) of patients diagnosed in March, April, and from May onwards, respectively, were treated in-line with VITT recommendations (p<0.001). Overall, treatment according to recommendations had no statistically significant influence on mortality (14/44 (32%) vs 29/55 (52%), adjusted OR 0.43 (95%CI 0.16-1.19)). However, patients who received immunomodulation had lower mortality (19/65 (29%) vs 24/34 (70%), adjusted OR 0.19 (95%CI 0.06-0.58)). Treatment with non-heparin anticoagulants instead of heparins was not associated with lower mortality (17/51 (33%) vs 13/35 (37%), adjusted OR 0.70 (95%CI 0.24-2.04)). Mortality was also not significantly influenced by platelet transfusion (17/27 (63%) vs 26/72 (36%), adjusted OR 2.19 (95%CI 0.74-6.54)). CONCLUSIONS In VITT-CVT patients, adherence to VITT treatment recommendations improved over time. Immunomodulation seems crucial for reducing mortality of VITT-CVT. This article is protected by copyright. All rights reserved.en600 - Technology::610 - Medicine & healtharticle10.48350/1706013568934610.1002/ana.26431